Research programme: catalytic antioxidants - Aeolus Pharmaceuticals

Drug Profile

Research programme: catalytic antioxidants - Aeolus Pharmaceuticals

Alternative Names: AEOL-10113; AEOL-11207

Latest Information Update: 08 Feb 2012

Price : $50

At a glance

  • Originator Duke University; National Jewish Medical and Research Center
  • Developer Aeolus Pharmaceuticals Inc
  • Class Porphyrins; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Epilepsy; Parkinson's disease; Radioprotection
  • Discontinued Asthma; Bronchitis; Cancer; Chronic obstructive pulmonary disease; Ischaemic heart disorders; Liver disorders; Reperfusion injury; Rheumatoid arthritis; Stomatitis; Stroke; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 07 Feb 2012 Preclinical pharmacodynamics data for AEOL 11207 released by Aeolus
  • 17 Aug 2011 Preclinical trials of Hexyl in Radiation injuries (Prevention)/Radioprotection in USA (unspecified route)
  • 17 Aug 2011 AEOL 11207 is still in preclinical trials for Parkinson's disease and Epilepsy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top